Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.
Department of Human Genetics and.
J Clin Invest. 2021 Dec 1;131(23). doi: 10.1172/JCI152386.
BackgroundThere is considerable variability in COVID-19 outcomes among younger adults, and some of this variation may be due to genetic predisposition.MethodsWe combined individual level data from 13,888 COVID-19 patients (n = 7185 hospitalized) from 17 cohorts in 9 countries to assess the association of the major common COVID-19 genetic risk factor (chromosome 3 locus tagged by rs10490770) with mortality, COVID-19-related complications, and laboratory values. We next performed metaanalyses using FinnGen and the Columbia University COVID-19 Biobank.ResultsWe found that rs10490770 risk allele carriers experienced an increased risk of all-cause mortality (HR, 1.4; 95% CI, 1.2-1.7). Risk allele carriers had increased odds of several COVID-19 complications: severe respiratory failure (OR, 2.1; 95% CI, 1.6-2.6), venous thromboembolism (OR, 1.7; 95% CI, 1.2-2.4), and hepatic injury (OR, 1.5; 95% CI, 1.2-2.0). Risk allele carriers age 60 years and younger had higher odds of death or severe respiratory failure (OR, 2.7; 95% CI, 1.8-3.9) compared with those of more than 60 years (OR, 1.5; 95% CI, 1.2-1.8; interaction, P = 0.038). Among individuals 60 years and younger who died or experienced severe respiratory failure, 32.3% were risk-variant carriers compared with 13.9% of those not experiencing these outcomes. This risk variant improved the prediction of death or severe respiratory failure similarly to, or better than, most established clinical risk factors.ConclusionsThe major common COVID-19 genetic risk factor is associated with increased risks of morbidity and mortality, which are more pronounced among individuals 60 years or younger. The effect was similar in magnitude and more common than most established clinical risk factors, suggesting potential implications for future clinical risk management.
在年轻成年人中,COVID-19 的结局存在相当大的变异性,其中一些变异可能归因于遗传易感性。
我们结合了来自 9 个国家的 17 个队列的 13888 名 COVID-19 患者(n = 7185 名住院患者)的个体水平数据,评估了主要常见 COVID-19 遗传风险因素(由 rs10490770 标记的染色体 3 位置)与死亡率、COVID-19 相关并发症和实验室值的关联。接下来,我们使用 FinnGen 和哥伦比亚大学 COVID-19 生物库进行了荟萃分析。
我们发现,rs10490770 风险等位基因携带者的全因死亡率风险增加(HR,1.4;95%CI,1.2-1.7)。风险等位基因携带者发生多种 COVID-19 并发症的几率增加:严重呼吸衰竭(OR,2.1;95%CI,1.6-2.6)、静脉血栓栓塞(OR,1.7;95%CI,1.2-2.4)和肝损伤(OR,1.5;95%CI,1.2-2.0)。60 岁及以下的风险等位基因携带者死亡或发生严重呼吸衰竭的几率高于 60 岁以上的风险等位基因携带者(OR,2.7;95%CI,1.8-3.9)(OR,1.5;95%CI,1.2-1.8;交互作用,P = 0.038)。在 60 岁及以下死亡或发生严重呼吸衰竭的个体中,32.3%为风险变异携带者,而未发生这些结局的个体中为 13.9%。与大多数既定的临床危险因素相比,这种风险变异同样或更好地改善了死亡或严重呼吸衰竭的预测。
主要常见的 COVID-19 遗传风险因素与发病率和死亡率的增加相关,在 60 岁及以下的个体中更为明显。这种效应的大小相似,比大多数既定的临床危险因素更为常见,这表明其可能对未来的临床风险管理具有重要意义。